Postoperative Chylothorax: Is Octreotide A Valid Therapy?

Octreotide for Chylothorax Due to Fibrosing Mediastinitis

51 Received June 11, 2010; revision accepted for publication August 9, 2010. doi: 10.1620/tjem.222.51 Correspondence: Young Hak Kim, M.D., Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto 606-8507, Japan. e-mail: [email protected] Octreotide, a Somatostatin Analogue, in the Treatment of Chylothorax Associated with Idi...

Octreotide for the Management of Chylothorax in newborns, case report

Chylothorax is the most common cause of pleural effusion in neonates. It is usually idiopathic. Neonatal chylothorax successfully respond to octreotide treatment and can reduce the duration of hospitalization. A number of therapeutic interventions have been used to reduce chyle production and promote resolution of a chylothorax. Initial management typically includes restriction or temporary ces...

Octreotide in the treatment of chylothorax.

Congenital neonatal chylothorax with hydrops fetalis treated with octreotide.

Congenital idiopathic chylothorax is the most common form of pleural effusion in neonates. It results from collection of lymphatic fluid in the pleural space secondary to leakage from the thoracic duct or one of its main tributaries. Chylothorax complicated by hydrops fetalis in a premature or term infant is an uncommon, serious clinical problem. We report on two cases with congenital chylothor...

The use of octreotide to treat congenital chylothorax.

We report the use of the octreotide (a somatostatin analogue) in the treatment of idiopathic congenital chylothorax in a patient with Turner's syndrome who had previously failed conservative medical therapy. The patient improved rapidly after initiation of octreotide with complete resolution after 5 days of continuous therapy (10 microg/kg per hour).